CJC/Ipamorelin or IGF-1 LR3? One is a signal. The other is the payload.
This is the most consequential distinction on this page: CJC-1295 with ipamorelin works upstream, prompting your own growth-hormone rhythm and keeping your body's feedback loops in the conversation. IGF-1 LR3 is downstream: a long-acting analog of the growth factor itself, past the feedback loops. That difference is not a detail. It is the difference between turning up a thermostat and holding a lighter to the sensor, and it is why the clinician's role here is not a formality.
The short answer
If you are choosing between them cold, the upstream option is where clinicians start: it works with your own axis, and your body retains a say. IGF-1 LR3 is the more direct and more serious tool, with more that deserves respect, and it is exactly the compound the grey market sells most casually. We prescribe both, which is precisely why we can afford to be honest about the order in which a careful clinician thinks about them. Arrive with your goal; leave the sequencing to the review.
Side by side
| CJC-1295 / Ipamorelin | IGF-1 LR3 | |
|---|---|---|
| Works | Upstream: prompts your own GH rhythm | Downstream: the growth factor itself, long-acting |
| Feedback loops | Kept in the conversation | Bypassed |
| Clinical posture | The usual starting point | The escalation that has to earn its place |
| The buyer | Training hard, recovery lagging the effort | The plateau that upstream signaling did not move |
| Regulatory status | Compounded to your prescription; not an FDA-approved drug product | Compounded to your prescription; not an FDA-approved drug product |
| Monthly cost | From $179/mo | From $179/mo |
Why does upstream vs downstream matter so much?
Because your endocrine system is a negotiation, and the two compounds treat it differently. A secretagogue pair asks your pituitary for more and lets your physiology answer. A direct growth factor states the answer. There are cases for each, but they are not interchangeable, and a seller who presents them as two flavors of the same thing is telling you they have no clinician in the building.
The grey-market difference
IGF-1 LR3 may be the most casually sold serious compound in the entire research-chemical economy. What changes here is the part that should never have been optional: a licensed clinician reviewing whether it belongs in your plan at all, and a licensed US pharmacy compounding what arrives. If a review says no, that no is the product working as designed.
Questions
What happens if I am not approved?
You are not charged. Your clinician explains the reasoning and, where useful, what a better next step may be. Reviews are typically completed in under 24 hours.
Are these FDA approved?
No compounded medication is FDA-approved, including these. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
Is either of these HGH?
No. One prompts your own growth-hormone axis; the other is a growth-factor analog. Neither is synthetic HGH, and neither is prescribed here as a substitute for it.
Ready when you are.
About 10 minutes. No charge unless your clinician approves.